On Tuesday, Danaher Corporation (NYSE:DHR)’s shares inclined 2.27% to $87.53.
Danaher Corporation (“Danaher,”) (DHR) declared the completion of its acquisition of Pall Corporation (“Pall,”) (PLL).
On August 31, 2015, Danaher accomplished the merger of Pentagon Merger Sub, Inc., a New York corporation and an indirect wholly owned partner of Danaher, into Pall and, as a result, Pall has become an indirect wholly owned partner of Danaher. In the merger, each outstanding share of Pall common stock was cancelled and (except for shares held by Danaher, Pentagon, Pall and their respective auxiliaries) converted into the right to receive $127.20 per share in cash, without interest.
Pall’s common stock will cease to be traded on the New York Stock Exchange. Detailed instructions will be sent to former Pall shareholders outlining the steps to be taken to obtain the merger consideration of $127.20 per share in cash, without interest.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company’s Test & Measurement segment provides test, measurement, and monitoring products that are used in electronic design, manufacturing, and technology development; hardware and software solutions to deploy, manage, and secure communication network technologies and services; and tools, toolboxes, and automotive maintenance equipment.
FirstEnergy Corp.(NYSE:FE)’s shares gained 1.93% to $31.18.
The FirstEnergy Foundation has donated $5,000 to the Greensburg (Pennsylvania) Community Development Corporation to assist with the renovation of a key building in the city’s shopping district.
The building, at 205 South Pennsylvania Avenue in downtown Greensburg, has been vacant for almost 15 years, but renovation work has begun to make it a suitable home for retail businesses and apartments.
FirstEnergy Corp., through its auxiliaries, generates, transmits, and distributes electricity in the United States. The company operates through Regulated Distribution, Regulated Transmission, and Competitive Energy Services segments. It owns and operates fossil, coal-fired, nuclear, oil and natural gas, wind and solar power, and hydroelectric generating facilities. The company also provides energy-related products and services to wholesale and retail customers.
At the end of Tuesday’s trade, Albemarle Corporation(NYSE:ALB)‘s shares surged 1.39% to $43.02.
Chemetall, a Global Business Unit of Albemarle Corporation (ALB), has introduced a new water-based penetrant for eco-friendly and process efficient fluorescent penetrant inspection. Britemor® 921 (W) enables bright and crisp indications on a wide range of materials, counting ferrous and non-ferrous metals, and non-porous ceramics, thanks to its very low fluorescent background and excellent wash characteristics. Chemetall’s liquid penetrant testing product uses water as the main carrier which is stabilized by a distinctive micro-emulsion technology. These micro-emulsions are thermodynamically stable and composition comprises isotropic liquid mixtures of solvent, water and emulsifier. The low viscosity of the Britemor® 921 (W) ensures minimal drag out, reduces overall product and rinse water consumption and minimizes the effluent treatment costs.
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. The company’s Performance Chemicals segment offers brominated flame retardants under the Saytex brand; mineral-based flame retardants under the Martinal and Magnifin brands; and elemental bromine, alkyl bromides, inorganic bromides, brominated powdered activated carbon, and bromine fine chemicals that are used in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, paper manufacturing, water purification, beef and poultry processing, and various other industrial applications.
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), ended its Tuesday’s trading session with 10.73% gain, and closed at $2.27.
Navidea Biopharmaceuticals, Inc. (NAVB) is announcing the receipt of an initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.8 million from the National Cancer Institute (NCI), National Institutes of Health (NIH), to fund preclinical studies examining the safety of intravenous(IV) injection of Tc99m tilmanocept, a Manocept™ platform product, followed by a clinical study providing the initial evaluation of the safety and efficacy of SPECT imaging studies with IV Tc99m tilmanocept to identify and quantify both skin- and organ-associated KS lesions in human patients.
The SBIR grant is awarded in two parts with the potential for total grant money of up to $1.8 million over two and a half years. The first six-month funding segment of $300,000, which has already been awarded, is predictable to enable Navidea to secure necessary collaborations and Institutional Review Board (IRB) approvals. The second funding segment could provide for up to an additional $1.5 million to be used to accrue participants, perform the Phase 1/2 study and perform data analyses to confirm the safety and effectiveness of intravenously administered Tc99m tilmanocept.
Navidea Biopharmaceuticals, Inc., a precision medicine company, focuses on the development and commercialization of precision diagnostics, therapeutics, and radiopharmaceutical agents. The company offers Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on macrophages.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
